Ibiglustat is an inhibitor of glucosylceramide synthase extracted from patent WO 2015089067 A1, compound example 64.
CAS：1401090-53-6
分子式：C20H24FN3O2S
分子量：389.49
纯度：98%
存储：Store at -20°C

Background:

Ibiglustat is an inhibitor of glucosylceramide synthase extracted from patent WO 2015089067 A1, compound example 64.

Ibiglustat is in phase II clinical trials for the treatment of Fabry’s disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy[2]. Substrate reduction therapy is an approach that reduces the synthesis of lipids reaching the lysosome through inhibition of glucosylceramide synthase (GCS)[1].

参考文献:
[1]. WO 2015089067 A1
[2]. Schiffmann R, et al. Fabry disease. Handb Clin Neurol. 2015;132:231-48.